Navigation Links
Pharmasset to Present at JMP Securities Healthcare Conference
Date:10/1/2009

PRINCETON, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the JMP Securities Healthcare Conference. The conference will be held at the New York Palace Hotel in New York City (October 5-6, 2009).

Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company on Tuesday, October 6, 2009 at 1:30 PM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following each presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys® plus Copegus® and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which has completed Phase 1 clinical studies, and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial.

Pegasys(®) and Copegus(® )are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including, without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended June 30, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

SOURCE Pharmasset, Inc.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmasset Reports Fiscal Third Quarter 2009 Financial Results
2. Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
3. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
4. Pharmasset to Present at Deutsche Bank Healthcare Conference
5. Pharmasset to Present at Two Upcoming Investor Conferences
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
8. Pharmasset to Webcast an Investor Event from the AASLD Meeting
9. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
10. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
11. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, ... priority because it’s not if you will be attacked, but when.” However, he and ... to digital health care. , Improvements in auditing and monitoring have taken security in ...
(Date:2/24/2017)... ... ... Healthcare Associates of McKinney announced today that they have moved one ... 121, Suite 210, McKinney, Texas 75070. It is in the heart of the ... has grown, the need for more space has been paramount. This beautiful new ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have ... Users have total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, ... Pro X. , With ProGlass Prism users are given the tools and effects ...
(Date:2/24/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a ... an astounding statement when he says that the entire Bible was written for the ... times so plainly that anyone should be able to see the time period. He ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly ... Dyer started as the Chairman of the Management Committee when IFN was originally ... including the recruitment of investor/owners and development of the business plan. He became ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Following receiving CE Marking in Europe ... AMAR is a major milestone for the country where the device was developed ... market in Israel   ... inclusion in the National Health Basket , Israel , ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced wound ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Global Empty Capsules Market is poised to grow at a ... billion by 2025. This industry report analyzes the market ... as regional levels presented in the research scope. The study provides historical ...
(Date:2/24/2017)... , Feb. 24, 2017 Physician General ... Drug and Alcohol Programs Jennifer Smith commended ... providing training for and using naloxone, a life-saving overdose ... McCullough , a recovery specialist and overdose survivor who ... EMS providers. "A significant part of fighting ...
Breaking Medicine Technology: